Mody, Kabir
Abou-Alfa, Ghassan K.
Article History
First Online: 11 January 2019
Compliance with Ethical Standards
:
: Kabir Mody has received research funding from Agios, Senwha Biosciences, Taiho, ArQule, Astra Zeneca, Genentech, Incyte, Tracon Pharmaceuticals, Medimmune, and Puma Biotechnology; and has received compensation from AstraZeneca, Bayer, Celgene, Eisai, Exelixis, Merrimack, and Vicus for service as a consultant.Ghassan K. Abou-Alfa has received research funding from ActaBiologica, Agios, Array, AstraZeneca, Bayer, Beigene, BMS, Casi, Celgene, Exelixis, Genentech, Halozyme, Incyte, Lilly, Mabvax, Novartis, OncoQuest, Polaris Puma, QED, and Roche; has received compensation from 3DMedcare, Agios, Alignmed, Amgen, Antengene, Aptus, Aslan, Astellas, Astra Zeneca, Bayer, Beigene, Bioline, BMS, Boston Scientifc, Bridgebio, Carsgen, Celgene, Casi, Cipla,CytomX, Daiichi, Debio, Delcath, Eisai, Exelixis, Genoscience, Gilead, Halozyme, Hengrui, Inovio, Ipsen, Jazz, Jansen, Kyowa Kirin, LAM, Lilly, Loxo, Merck, Mina, Newlink Genetcis, Novella, Onxeo, PCI Biotech, Pfizer, Pharmacyte, Pharmacyclics, Pieris, QED, Redhill, Sanofi, Servier, Silenseed, Sillajen, Sobi, Targovax, Tekmira,Twoxar, Vicus, Yakult, and Yiviva for service as a consultant; and has patents for articles and methods for preventing and treating dermatologic adverse events issued and licensed.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
Free to read: This content has been made available to all.